Alpha-fetoprotein (AFP), the most widely studied serum biomarker for HCC, correlates with viable tumor burden [14]; however, only half of patients with HCC have elevated AFP prior to Tx[15], limiting its utility to assess HCC TR. Here, AFP is linked to hepatocellular carcinoma.